Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Escitalopram in Pediatric Major Depressive Disorder
NCT00107120Phase 3Completed
- Sponsor
- Forest Laboratories
- Start
- Mar 2005
- Primary completion
- May 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Escitalopram with Placebo (2 arms). Primary endpoint: Children's Depression Rating Scale - Revised Total Score at 8 weeks. Started Mar 2005; status: completed.
02
Drugs
escitalopram
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00107120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00107120.